Dr. Greg M. Delgoffe profile page

Greg M. Delgoffe, PhD is an Associate Professor of Immunology at the University of Pittsburgh and Director of the Tumor Microenvironment Center at UPMC Hillman Cancer Center. Since its inception in 2014, Dr. Delgoffe’s research group has been interested in the metabolic underpinnings of tumor-induced immune suppression. His group has discovered that T cell exhaustion is a metabolic phenotype, and that tumor tissue can support tolerogenic populations like regulatory T cells. His group works to translate fundamental observations into therapeutic modalities that can leverage metabolism for immunologic benefit. His research has been recognized through several awards, including the AACR NextGen Star Award, the NIH Director’s New Innovator Award, and he has been a Clarivate Highly Cited Research in Immunology since 2022. A member of the National Academy of Inventors, Dr. Delgoffe also has developed a number of novel treatment approaches to leverage immunometabolism in cancer therapy, which formed the basis of a number of start-up companies.